SEC Form 4 · accession 0001209191-15-057984
IDERA PHARMACEUTICALS, INC. · IDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J Casey
Officer — Senior VP and General Counsel
Period of report
Jun 29, 2015
Accepted (ET)
Jul 1, 2015 · 4:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000861838
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $3.44 | Jun 29, 2015 | A | 325,000 | A | — | Jun 29, 2025 | Common Stock | 325,000 | 325,000 | D |
| Stock OptionF2 | $3.44 | Jun 29, 2015 | A | 275,000 | A | — | Jun 29, 2025 | Common Stock | 275,000 | 275,000 | D |
Explanation of responses
- F1This option was granted under the Company's 2013 Stock Incentive Plan. The option vests with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vests in twelve equal quarterly installments following the first anniversary of the date of grant.
- F2This option was not granted pursuant to any pre-existing equity plan of the Company. Instead, this option was made as an inducement grant pursuant to Nasdaq Listing Rule 5635(c)(4) in connection with the reporting person's appointment as Senior Vice President and General Counsel. The option vests with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vests in twelve equal quarterly installments following the first anniversary of the date of grant.